Clinical Trial Update: Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ibrutinib plus Rituximab-CHOP in Epstein-Barr virus-positive diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus-positive Diffuse Large B-cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Rituximab-CHOP (Rituximab-CHOP)

Snippet

Sponsor: Samsung Medical Center | Conditions: Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma | Phase 2 | Status: COMPLETED